Quick Answer
GYRE THERAPEUTICS, INC. reported Revenue From Contract With Customer Excluding Assessed Tax of $116.59 million for the year ending 2025.
- GYRE THERAPEUTICS, INC. showed an increase of +10.2% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from GYRE THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2017 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $111.0 thousand | Q3 2017: $318.0 thousand | Q1 2018: $6.0 thousand | Q1 2020: $16.37 million | Q2 2020: $1.66 million | Q3 2020: $893.0 thousand | Q1 2021: $1.47 million | Q2 2021: $1.13 million | Q3 2021: $2.30 million | Q1 2022: $794.0 thousand | Q1 2023: $24.93 million | Q2 2023: $29.33 million | Q3 2023: $32.04 million | Q1 2024: $27.17 million | Q2 2024: $25.23 million | Q3 2024: $25.49 million | Q1 2025: $22.06 million | Q2 2025: $26.77 million | Q3 2025: $30.56 million.
- Over the full 8 years of available data (2017 to 2025), GYRE THERAPEUTICS, INC.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 11,352.7%.
- Historical annual values: Fiscal year 2025: $116.59 million | Fiscal year 2024: $105.76 million | Fiscal year 2023: $113.45 million | Fiscal year 2022: $102.29 million | Fiscal year 2021: $7.34 million | Fiscal year 2020: $20.95 million | Fiscal year 2018: $6.0 thousand | Fiscal year 2017: $1.02 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: